RT Journal Article
SR Electronic
T1 Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.10.22272100
DO 10.1101/2022.03.10.22272100
A1 Michael Dougan
A1 Masoud Azizad
A1 Peter Chen
A1 Barry Feldman
A1 Matthew Frieman
A1 Awawu Igbinadolor
A1 Princy Kumar
A1 Jason Morris
A1 Jeffrey Potts
A1 Lauren Baracco
A1 Lisa Macpherson
A1 Nicole L. Kallewaard
A1 Dipak R. Patel
A1 Matthew M. Hufford
A1 Linda Wietecha
A1 Emmanuel Chigutsa
A1 Sarah L. Demmon
A1 Bryan E. Jones
A1 Ajay Nirula
A1 Daniel M. Skovronsky
A1 Mark Williams
A1 Robert L. Gottlieb
YR 2022
UL http://medrxiv.org/content/early/2022/03/12/2022.03.10.22272100.abstract
AB BACKGROUND Bebtelovimab is a potent, fully human IgG1 monoclonal antibody (mAb) targeting the S-protein of SARS-CoV-2, with broad neutralizing activity to all currently known SARS-CoV-2 variants of concern, including omicron variant lineages. Specialized developmental approaches accelerated the initiation of a clinical trial designed to evaluate the efficacy and safety of bebtelovimab alone (BEB) or together with bamlanivimab (BAM) and etesevimab (ETE) delivered via slow intravenous push for the treatment of mild-to-moderate COVID-19.METHODS This portion of the phase 2, BLAZE-4 trial (J2X-MC-PYAH; NCT04634409) enrolled 714 patients (between May and July 2021) with mild-to-moderate COVID-19 within 3 days (≤3 days) of laboratory diagnosis of SARS-CoV-2 infection. Patients at low risk for severe COVID-19 were randomized 1:1:1 (double-blinded) to placebo, BEB 175 mg, or BEB 175 mg+BAM 700 mg+ETE 1400 mg (BEB+BAM+ETE). Patients at high risk for progression to severe COVID-19 were randomized 2:1 (open-label) to BEB or BEB+BAM+ETE, and a subsequent treatment arm enrolled patients to BEB+BAM+ETE using Centers for Disease Control and Prevention (CDC) updated criteria for High-risk. All treatments were administered intravenously over ≥30 seconds (open-label BEB) or ≥6.5 minutes (all other treatment arms). For the placebo-controlled patients (termed Low-risk), the primary endpoint was the proportion of patients with persistently high viral load (PHVL) (log viral load >5.27) on Day 7. For the open-label patients (termed High-risk), the primary endpoint was safety. In nonclinical studies, SARS-CoV-2 isolates were tested using an endpoint neutralization assay to measure BEB’s inhibitory concentration greater than 99% (IC99).RESULTS Baseline viral sequencing data were available from 611 patients; 90.2% (n=551) aligned with a variant of interest or concern (WHO designation), with the majority infected with delta (49.8%) or alpha (28.6%) variants. Among the Low-risk patients, PHVL occurred in 19.8% of patients treated with placebo, as compared to 12.7% (p=0.132) of patients treated with BEB+BAM+ETE and 12.0% (p=0.097) of patients treated with BEB, a 36% and 40% relative risk reduction, respectively. Viral load-area under the curve analysis from baseline to Day 11 showed statistically signficant reductions for patients treated with BEB (p=0.006) and BEB+BAM+ETE (p=0.043) compared to patients who received placebo. Time to sustained symptom resolution was reduced by a median of 2 days for patients treated with BEB (6 days; p=0.003) and 1 day for patients treated with BEB+BAM+ETE (7 days; p=0.289) compared to placebo (8 days). The incidence of COVID-19-related hospitalization or all-cause deaths by day 29 were similar across treatment arms, as expected given the patients’ risk status (the Low risk cohorts had a Low risk of hospitalization, and High risk cohorts received only active therapy without placebo). Overall, safety results were consistent with previous studies investigating mAbs targeting SARS-CoV-2. The proportion of patients with treatment emergent adverse events (AEs) were 9.7% in Low-risk (n=37/380) and 14.7% in High-risk (n=48/326) patients treated with BEB or BEB+BAM+ETE; majority of AEs were considered mild or moderate in severity. Serious AEs were reported in 2.1% of High-risk patients (n=7/326), including one death (a cerebrovascular accident); 1 serious AE was reported among Low-risk patients. In an in vitro neutralization assay, BEB neutralized the omicron isolate (BA.1) with <2.44ng/ml estimated IC99.CONCLUSIONS In patients with mild-to-moderate COVID-19, treatment with BEB or BEB+BAM+ETE was associated with greater viral clearance, a reduction in time to sustained symptom resolution, and safety results consistent with mAbs that target SARS-CoV-2. Integration of clinical findings with in vitro neutralization of emerging viral variants offered a pragmatic framework for investigating the efficacy of a new antiviral mAb agent, as demonstrated by bebtelovimab.Competing Interest StatementMixed Competing Interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. Michael Dougan (M.D.) received support for the present manuscript from Eli Lilly and Company. M.D. reports payments made to Massachusetts General Hospital in the form of grants or contracts from Eli Lilly and Company and Novartis; consulting fees received from Tillotts Pharma, ORIC Pharmaceuticals, Partner Therapeutics, SQZ Biotech, AzurRx and Neoleukin Therapeutics (where he is also on the Scientific Advisor Board); payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from WebMD, Experts at Your Fingertips, Sandoz Academy, UpToDate and Eli Lilly and Company; payments received from Mallinckrodt Pharmaceuticals and Moderna for participation on a data safety monitoring board or advisory board, and stock or stock options from Neoleukin Therapeutics. Peter Chen (P.C.) received grants or contracts from Eli Lilly and Company, consulting fees from Eli Lilly and Company, Regeneron and Gilead, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Rockpointe, Frontier Collaborative, Physician Education Resource and CME Outfitter. Barry Feldman is on the Michigan Healthcare Board of Directors. Matthew Frieman (M.F.) reports support for the present manuscript from BARDA/HHS in the form of funding for the neutralization assays which were performed on the monoclonal antibodies provided by Eli Lilly and Company for this work. M.F. additionally reports funding received from Regeneron and Astrazeneca for the neutralizing antibody testing, and consulting fees received from Observatory Group and Aikido Pharma (on which he is also a scientific advisory board member). Princy Kumar (P.K.) reports grants or contracts paid to Georgetown University from Eli Lilly and Company, GSK, Merck, Gilead, Regeneron, American Gene Technologies, and BioHaven. P.K. reports payments received from Johnson&Johnson, ViiV, Gilead, TheraTechnologies and Merck for participation on a Data Safety Monitoring Board or Advisory Board, and stock or stock options with Merck, Johnson&Johnson, GSK, Gilead, Pfizer and Moderna. Jason Morris reports payments to the clinical trial site from Eli Lilly and Company. Lisa Farmer McPherson, Nicole Kallewaard (N.K.), Dipak Patel, Matthew Hufford (M.H.), Linda Wietecha, Emmanuel Chigutsa, Sarah Demmon, Bryan Jones (B.J.), Ajay Nirula, Daniel Skovronsky (D.S.) and Mark Williams are employees and stockholders at Eli Lilly and Company. N.K, M.H. and B.J. additionally report support for attending meetings and/or travel from Eli Lilly and Company. N.K. reports support for attending meetings and/or travel from Astrazeneca, and is a former employee and stockholder at Astrazeneca. B.J. is a named inventor on patent applications related to bebtelovimab. D.S. reports an additional relationship with Eli Lilly and Company regarding patents planned, issued or pending. Robert Gottlieb (R.L.G.) reports support for the present manuscript in the form of fees paid by Eli Lilly and Company to Baylor Scott & White Research Institute; grants or contracts received from Regeneron in the form of fees paid to Baylor Scott & White Research Institute; consulting fees received from Gilead Sciences and GSK Pharmaceuticals; participation on the COVID-19 Advisory Board at Eli Lilly and Company, Gilead Sciences, GSK and Roche/Genetech, participation as a COVID-19-related Randomized Clinical Trial Co-ordinating Principal Investigator for Johnson&Johnson, Study Investigator at Kinevant Sciences with fees paid to Baylor Scott & White Research Institute, de minimis stock of AbCellera, and a gift-in-kind of medication to Baylor Scott & White Research Institute for Investigator-sponsored trial TROJAN-C (NCT03383419) from Gilead Sciences, Inc. For all other authors, no relationships or activities that could appear to have influenced the submitted work were reported.Clinical TrialNCT04634409Funding StatementThis study was funded by Eli Lilly and CompanyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB/IEC for each investigator site involved in the Blaze-4 study reviewed and approved the PYAH protocol prior to study initiation and included Western Institutional Review Board, Baylor Scott & White Research Institute, St. Vincent's Institutional Review Board, and Copernicus Group Independent Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.